Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)-MedSci.cn

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung (vol 35, pg 412, 2017)

Paz-Ares, L

Paz-Ares, L (reprint author), Univ Seville, Seville, Spain.

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (8): 833

科室
- - 订阅+
  - 更多科室
工具
服务